Loading
AT
Artemis Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Culley Brian M, was filed 25 Oct 2017.
Artemis Therapeutics, Inc.: what insiders have been doing
Artemis Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Artemis Therapeutics, Inc. in twelve months, the latest record being from 19 December 2018.
Since 2006, the database holds 7 purchases and 16 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€747,999
7 ops. · all time
Sell Volume
€339,736
16 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Revenue277.2k
Gross profit229.1k83% margin
Net income-1.2M-435.7% margin
Last declaration on 19 December 2018
Declarations30 total
182 shares@ US$0.2601100.0% of flowCommon StockSEC:0001178913-18-003163:0
25,000 sharesCommon StockSEC:0001178913-17-002876:0
Canonical exit: 21 Jan 2018 (T+90)
35,202 shares@ US$0.01100.0% of flowCommon StockSEC:0001178913-17-001935:0
2,055,604 shares0Common StockSEC:0001178913-12-000458:0
10,000 shares@ US$0.18Common StockSEC:0001178913-11-000707:0
48,611 shares@ US$0.18Common StockSEC:0001178913-11-000695:0
277,778 shares@ US$0.18Common StockSEC:0001178913-11-000699:0
62,500 shares@ US$0.18Common StockSEC:0000891092-11-001515:0
45,000 shares@ US$0.1467Common StockSEC:0001178913-10-002715:0
19,000 shares@ US$0.15Common StockSEC:0001178913-10-002715:1
3,200,000 shares@ US$0.125Common StockSEC:0001178913-10-000828:0
Canonical exit: 9 Jun 2010 (T+90)
1,600,000 shares@ US$0.125Common StockSEC:0001178913-10-000828:2
Canonical exit: 9 Jun 2010 (T+90)
200,000 shares@ US$0.125Common StockSEC:0001178913-10-000804:0
Canonical exit: 9 Jun 2010 (T+90)
800,000 shares@ US$0.125Common StockSEC:0001178913-10-000802:0
Canonical exit: 9 Jun 2010 (T+90)
2,000,000 shares@ US$0.125Common StockSEC:0001178913-10-000794:0
Canonical exit: 9 Jun 2010 (T+90)
25,000 shares@ US$1.90Common StockSEC:0001178913-07-000705:0
Canonical exit: 28 Jun 2007 (T+90)
155,000 shares@ US$1.90Common StockSEC:0000891092-07-001191:0
7,000 shares0Common StockSEC:0001178913-07-000030:0
7,000 shares0Common StockSEC:0001178913-06-002335:0
1,000 shares@ US$3.10Common Stock, par value $0.01 per shareSEC:0001178913-06-002312:0
5,000 shares@ US$2.75Common Stock, par value $0.01 per shareSEC:0001178913-06-002295:0
4,000 shares@ US$2.80Common Stock, par value $0.01 per shareSEC:0001178913-06-002295:1
1,000 shares@ US$2.80Common Stock, par value $0.01 per shareSEC:0001178913-06-002295:2
5,000 shares@ US$3.00Common Stock, par value $0.01 per shareSEC:0001178913-06-002295:3
1,000 shares@ US$2.50Common Stock, par value $0.01 per shareSEC:0001178913-06-002228:0
25 of 30 declarations
About Artemis Therapeutics, Inc.
Artemis Therapeutics, Inc. is a company focused on developing innovative therapies for serious diseases. It is listed on the XNAS market.
